Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray

摘要: Molecular phenotyping and tissue microarray (TMA) studies have identified distinct invasive breast carcinoma subtypes: Luminal A, luminal B, enriched with overexpressed human epidermal growth factor receptor 2 (HER-2) triple-negative, i.e., negative for HER-2, as well estrogen progesterone (ER PR, respectively) expression. These subtypes are useful in clinical management, since they bear prognoses predictive responses to targeted therapy. However, although molecular profiling provides important prognostic indicators, cancer risk stratification remains a challenge triple-negative cases. What is referred claudin-low subtype was subset that associated more aggressive tumor behavior worse prognosis. the immunohistochemical expression of claudins has not yet been standardized. Our objective verify whether immunoexpression 4 7 (the main specifically expressed tissue) TMA survival prognosis HER-2 subtypes. In this diagnostic study, we investigated ER/PR status, claudin stem cell CD44/24 profiles, verified association outcomes 803 cases arranged four TMAs. Among these, 503 (62.6%) were positive 369 (46.0%) 7. Claudin exhibited lowest A subtypes, highest frequency HER-2-enriched whereas staining any subtype. The phenotype subgroups or profile able distinguish between patients better prognosis, it correlated Therefore, may be concluded 7, individually within usual context (ER, PR HER-2), does provide additional information on